We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$11.5B
1-Year Est. Return
168.77%
This Fund
S&P 500
This Quarter
Est. Return
-13.03%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$696M
AUM Growth
-$298M
(-30%)
Cap. Flow
-$15M
Cap. Flow
% of AUM
-2.15%
Top 10 Holdings %
Top 10 Hldgs %
54.99%
Holding
76
New
17
Increased
7
Reduced
14
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$30.3M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$21.6M |
| 3 |
AIMT
Aimmune Therapeutics
AIMT
|
+$18.5M |
| 4 |
Neurogene
NGNE
|
+$17.6M |
| 5 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
+$17.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDCO
Medicines Co
MDCO
|
+$20.2M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$18.8M |
| 3 |
DVAX
Dynavax Technologies
DVAX
|
+$17.9M |
| 4 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
+$14.9M |
| 5 |
Novavax
NVAX
|
+$14.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.5% |
| 2 | Miscellaneous | 7.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACHN
1
DELISTED
Achillion Pharmaceuticals
ACHN
| $81.1M | 11.64% |
11,733,815
+1,787,818
| +18% | +$14.6M |
|
|
SIOX
2
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $64.6M | 9.28% |
625,000
| – | – |
|
|
DYAX
3
DELISTED
DYAX CORPORATION
DYAX
| $48.7M | 6.99% |
2,551,193
-151,900
| -6% | -$3.63M |
|
4
Collegium Pharmaceutical
COLL
$711M
| $34.3M | 4.93% |
1,553,175
+7,765
| +0.5% | +$140K |
|
5
TG Therapeutics
TGTX
$8.12B
| $31.5M | 4.52% |
3,124,480
-177,733
| -5% | -$2.65M |
|
|
RGLS
6
DELISTED
Regulus Therapeutics
RGLS
| $26.4M | 3.79% |
33,665
+2,078
| +7% | +$2.13M |
|
7
Coherus Oncology
CHRS
$205M
| $26.2M | 3.76% |
1,305,020
-75,300
| -5% | -$2.29M |
|
8
Ascendis Pharma A/S
ASND
$15.8B
| $25.9M | 3.71% |
1,461,268
-451,885
| -24% | -$8.8M |
|
|
ZGNX
9
DELISTED
Zogenix, Inc.
ZGNX
| $22.7M | 3.26% |
+1,679,500
| New | +$30.3M |
|
|
10
Neurogene
NGNE
$674M
| $21.6M | 3.1% |
+76,608
| New | +$17.6M |
|
11
Protara Therapeutics
TARA
$222M
| $21M | 3.01% |
37,672
| – | – |
|
|
AIMT
12
DELISTED
Aimmune Therapeutics
AIMT
| $20M | 2.87% |
+790,200
| New | +$18.5M |
|
|
DRNA
13
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $19.9M | 2.86% |
2,428,571
| – | – |
|
|
GBT
14
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $19.3M | 2.77% |
+457,142
| New | +$21.6M |
|
|
BPMC
15
DELISTED
Blueprint Medicines
BPMC
| $18.7M | 2.69% |
878,348
| – | – |
|
16
Ardelyx
ARDX
$878M
| $18.4M | 2.64% |
1,064,013
-655,932
| -38% | -$12.2M |
|
|
CDTX
17
DELISTED
Cidara Therapeutics
CDTX
| $15M | 2.16% |
59,029
+1,962
| +3% | +$561K |
|
|
BLUE
18
DELISTED
bluebird bio
BLUE
| $14.3M | 2.06% |
12,921
+4,477
| +53% | +$8.16M |
|
|
19
BioCryst Pharmaceuticals
BCRX
$2.09B
| $13.6M | 1.96% |
1,196,603
-1,408,758
| -54% | -$18.8M |
|
|
ITCI
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.6M | 1.81% |
+314,349
| New | +$10.3M |
|
|
SRRA
21
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $12.4M | 1.78% |
+15,125
| New | +$17.1M |
|
22
Arcturus Therapeutics
ARCT
$450M
| $11.1M | 1.59% |
261,844
+43,859
| +20% | +$2.31M |
|
23
TherapeuticsMD
TXMD
$25M
| $8.9M | 1.28% |
30,369
-3,239
| -10% | -$1.15M |
|
|
NDRM
24
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $8.79M | 1.26% |
+425,000
| New | +$8.72M |
|
25
Natera
NTRA
$50.6B
| $8.5M | 1.22% |
+783,521
| New | +$13.3M |
|
Similar funds
AAIS
MG
CC
AI
BMSSC
HTC
WAM
RA Capital Management's Q3 2015 Portfolio in Review
As of Q3 2015, RA Capital Management held 76 positions worth $696M, down 30% from $994M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
RA Capital Management's Q3 2015 filing shows 17 new, 7 increased, 14 reduced and 29 closed positions. Its largest new stake was Zogenix, Inc.: 1,679,500 shares worth $22.7M. The largest sale was Medicines Co, an estimated $20.2M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 86% a quarter earlier, followed by Miscellaneous.
- RA Capital Management's largest Q3 2015 buy was Zogenix, Inc.: 1,679,500 shares worth $22.7M.
- RA Capital Management added most to Achillion Pharmaceuticals in Q3 2015, an estimated $14.6M increase.
- RA Capital Management's biggest Q3 2015 reduction was BioCryst Pharmaceuticals, cutting an estimated $18.8M.
- RA Capital Management fully exited Medicines Co in Q3 2015, selling an estimated $20.2M.
- RA Capital Management's ten largest holdings make up 55% of its $696M portfolio in Q3 2015.
- RA Capital Management opened 17 new positions and closed 29 in Q3 2015.
- RA Capital Management's portfolio value fell 30% quarter-over-quarter to $696M.
Based on RA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.